Hematology NewsMaintenance rituximab extends progression-free but not overall survival in CLLJune 8, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsDr. Matt Kalaycio’s top 10 hematologic oncology abstracts for ASCO 2016May 27, 2016CMLAMLCLLT Cell LymphomasFollicular Lymphoma
Hematology NewsVenetoclax achieves responses in CLL refractory to ibrutinib, idelalisibMay 26, 2016CLLLeukemia, Myelodysplasia, Transplantation
Oncology PracticeCAR T-cell start-up launchedMay 10, 2016Leukemia, Myelodysplasia, TransplantationCLL
Hematology News‘Universal’ CAR T cell may overcome limitationsApril 28, 2016Leukemia, Myelodysplasia, TransplantationALLCLL
Hematology NewsNew single-tube assay detects one CLL cell in 1 million leukocytesApril 27, 2016CLLIndolent LymphomaLeukemia, Myelodysplasia, Transplantation
Hematology NewsVP Biden to AACR: Help me help youApril 21, 2016Patient & Survivor CarePractice ManagementCLLCMLIndolent LymphomaBusiness of Medicine
Hematology NewsIn newly diagnosed CLL, mutation tests are advisedApril 13, 2016CLLCMLIndolent LymphomaLeukemia, Myelodysplasia, Transplantation
Hematology NewsFDA approves venetoclax for CLL with 17p deletionApril 11, 2016Indolent LymphomaLeukemia, Myelodysplasia, TransplantationCLL
Hematology NewsFeds advance cancer moonshot with expert panel, outline of goalsApril 5, 2016CMLCLLIndolent LymphomaMultiple MyelomaBreast CancerGenitourinary CancerGynecologic Cancer
Hematology NewsRPS15 mutations prevalent in aggressive chronic lymphocytic leukemiaMarch 16, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsIdelalisib use halted in six combo therapy trials, FDA announcesMarch 15, 2016Indolent LymphomaCLLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology NewsIbrutinib approved as first-line therapy for all CLL patientsMarch 7, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsVenetoclax shows promise for relapsed CLL, SLLFebruary 4, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsAcalabrutinib yields 95% overall response in relapsed CLLJanuary 27, 2016CLLLeukemia, Myelodysplasia, Transplantation
